Trial Profile
The effect of growth hormone replacement (GHR) on quality of life, physical and cardiovascular risk in conventionally replaced TBI (traumatic brain injury) induced growth hormone deficient (GHD) hypopituitary adults
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Somatotropin deficiency
- Focus Pharmacodynamics
- Sponsors Merck Serono; Roche
- 14 Jul 2010 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network record.
- 04 Feb 2009 New trial record